Back
 JBM  Vol.5 No.11 , November 2017
Nodular Amyloidosis Overlapping and Polymyositis in a Patient with Skin Manifestations Lupus Fax: Case Report
Abstract: Amyloidosis is the result of fibrous and insoluble amyloid protein deposition in extracellular spaces of tissues and organs, including the skin. Through the analysis of medical records, clinical condition and laboratory tests, this article proposes a rare case report of an adult patient with symptoms and diagnosis of polymyositis, histopathology of nodular amyloidosis with skin lesions suggestive of lupus. The patient is still being followed at the dermatology clinic of Valença Medical School, in order to improve the prognosis and prevent the progression of existing symptoms.
Cite this paper: do Bem Filho, E. , dos Santos Couto, L. , da Costa Soares Jr., A. , Andrade, P. , Miguel, T. , Filho, S. , da Costa, D. , de Melo Pino, L. and do Bem, T. (2017) Nodular Amyloidosis Overlapping and Polymyositis in a Patient with Skin Manifestations Lupus Fax: Case Report. Journal of Biosciences and Medicines, 5, 33-40. doi: 10.4236/jbm.2017.511005.
References

[1]   Annes, M., et al. (1997) Amiloidose. Rev. Neurociências, 1, 7-13.

[2]   Konopinski, J.C., Seyfer, S.J., Robbins, K.L. and Hsu, S. (2013) A Case of Nodular Cutaneous Amyloidosis and Review of the Literature. Dermatology Online Journal, 19, 10.

[3]   Woollons, A. and Black, M.M. (2001) Nodular Localized Primary Cutaneous Amyloidosis: A Long-Term Follow-Up Study. British Journal of Dermatology, 145, 105-109.
https://doi.org/10.1046/j.1365-2133.2001.04291.x

[4]   Moon, A.O., Calamia, K.T. and Walsh, J.S. (2003) Nodular Amyloidosis: Review and Long-Term Follow-Up of 16 Cases. Archives of Dermatology, 139, 1157-1159.
https://doi.org/10.1001/archderm.139.9.1157

[5]   Azulay, R.D. and Azulay, D.R. (2004) Dermatologia. 4th Edition, Guanabara Koogan, Rio de Janeiro, 664 p.

[6]   Marie, I., Hachulla, E., Chérin, P., et al. (2005) Opportunistic Infections in Polymyositis and Dermatomyositis. Arthritis Care & Research, 53, 155-165.
https://doi.org/10.1002/art.21083

[7]   Lupi, O. and Cunha, P.R. (2012) Rotinas de Diagnóstico e Tratamento da Sociedade Brasileira de Dermatologia. Editora Gen, Rio de Janeiro, 680 p.

[8]   Mcelhone, K., Abbott, J. and Teh, L.-S. (2006) A Review of Health Related Quality of Life in Systemic Lupus Erythematosus. Lupus, 15, 633-643.
https://doi.org/10.1177/0961203306071710

[9]   Telles, R.W., Lanna, C.C.D., Souza, F.L., Rodrigues, L.A., Reis, R.C.P. and Ribeiro, A.L. (2013) Causes and Predictors of Death in Brazilian Lupus Patients. Rheumatology International, 33, 467-473.
https://doi.org/10.1007/s00296-012-2372-x

[10]   Wolfe, F., Petri, M., Alarcón, G.S., Goldman, J., Chakravarty, E.F., Katz, R.S., et al. (2009) Fibromyalgia. Systemic Lupus Erythematosus (SLE) and Evaluation of SLE Activity. The Journal of Rheumatology, 36, 82-88.

[11]   Bohan, R. (1988) History and Classification of Polymyositis and Dermatomyositis. Nova Iorque. Clinics in Dermatology, 6, 3-8.

[12]   Breatmatch, S.M. (2010) Amyloid and the Amyloidosis of the Skin. In: Burns, T., Breathnach, S., Cox, N. and Griffiths, C., Eds., Rook’s Textbook of Dermatology, Wiley-Blackwell, 42-59.

[13]   Lachance, A., et al. (2014) Nodular Localized Primary Cutaneous Amyloidosis: A Bullous Variant. Clinical and Experimental Dermatology, 39, 344-347.
https://doi.org/10.1111/ced.12305

[14]   Lachmann, H.J., Goodman, H.J., Gilbertson, J.A., Gallimore, J.R., Sabin, C.A., Gillmore, J.D. and Hawkins, P.N. (2007) Natural History and Outcome in Systemic AA Amyloidosis. The New England Journal of Medicine, 356, 2361-2371.
https://doi.org/10.1056/NEJMoa070265

[15]   Souza, J.J., et al. (2011) Amiloidose Localizada Cutanea Primária Nodular Relato de caso. Anais Brasileiros De Dermatologia, 86, 987-990.
https://doi.org/10.1590/S0365-05962011000500018

[16]   Hoffman, B.J. (1945) Sensitivity to Sufadizine Resembling Acute Disseminated Lupus Erythematosus. Archives of Dermatological Research, 51, 90-92.

[17]   Bronner, M., Van Der Meulen, M., De Visser, M., et al. (2006) Long-Term Outcome in Polymyositis and Dermatomyositis. Nova Iorque. Annals of the Rheumatic Diseases, 65, 1456-1461.
https://doi.org/10.1136/ard.2005.045690

[18]   Esposito, A.C.C., Munhoz, T., Ocanha, J.P. and Miot, H.A. (2016) Syndrome in Question. Anais Brasileiros de Dermatologia, 91, 387-389.
https://doi.org/10.1590/abd1806-4841.20164298

[19]   Travassos, A.R., Borges-Costa, J., Filipe, P. and Marques, M.S. (2013) Malignancy Associated with Dermatomyositis—A Retrospective Single-Center Study with 33 Patients. Acta Reumatológica Portuguesa, 38, 92-97.

[20]   Ortigosa, L.C.M. and dos Reis, V.M.S. (2014) Dermatomyositis: Analysis of 109 Patients Surveyed at the Hospital das Clínicas (HCFMUSP), Sao Paulo, Brazil. Anais Brasileiros de Dermatologia, 89, 719-727.
https://doi.org/10.1590/abd1806-4841.20143422

[21]   Chahin, N. and Engel, A. (2008) Correlation of Muscle Biopsy, Clinical Course, and Outcome in PM and Sporadic IBM. Nova Iorque. Neurology, 70, 418-424.
https://doi.org/10.1212/01.wnl.0000277527.69388.fe

[22]   Ciber, J., Sibley, J. and Haga, M. (2001) Systemic Lupus Erythematosus and the Risk of Malignancy. Lupus, 10, 394-400.
https://doi.org/10.1191/096120301678646128

[23]   Hurd, K. and Barnabe, C. (2017) Systematic Review of Rheumatic Disease Phenotypes and Outcomes in the Indigenous Populations of Canada, the USA, Australia and New Zealand. Rheumatology International, 37, 503-521.
https://doi.org/10.1007/s00296-016-3623-z

[24]   Magro-Checa, C., Zirkzee, E.J., Huizinga, T.W. and Steup-Beekman, G.M. (2016) Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives. Drugs, 76, 459-483.
https://doi.org/10.1007/s40265-015-0534-3

[25]   Barros, R., Alves, M. and Dantas, M. (2006) Glomerulopatias—Patogenia clínica e tratamento. 2nd Edition, Sarvier, Sao Paulo, 288-298.

 
 
Top